Epivax
Business Services · Rhode Island, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
188 Valley St Ste 424, Providence, Rhode...Phone Number
(401) 272-2123Website
www.epivax.comRevenue
$7.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Epivax
EpiVax is an American biotechnology firm headquartered in Providence, Rhode Island that specialises in immunoinformatics and immunogenicity risk assessment to support vaccine and biologic drug development. The company uses advanced computational and laboratory methods to help partners optimise therapeutic safety and efficacy and mitigate immune response risks. It collaborates with pharmaceutical companies, regulatory agencies and academic institutions to improve global health outcomes.EpiVax is viewed as a leader in computational immunology, providing critical tools for vaccine design and biologics safety. Industry observers highlight its integration of AI-driven predictions with laboratory validation, which helps pharmaceutical partners accelerate development while reducing immunogenicity-related risks.Explore more
Epivax Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Epivax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Epivax
Funding: Get notified immidiatlly once Epivax has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Epivax has recently received funding, and reach out quickly before it becomes old news!
Check out if Epivax is spiking on competitors!
Product Launch: Get notified when Epivax launches new products
Earning: See what the market has to say on Epivax recently announced quarterly report
Epivax, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Epivax had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Epivax
Find more new buyers
Compare Similar Companies to Epivax
Compare insights from companies similar to Epivax, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Epivax is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Epivax is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Epivax.
Epivax financials insights
Gather financial insights about Epivax, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Grant
$368K
2008
Grant
$600K
Grant
$390K
2011
Grant
$458K
2012
Multiple Rounds
$1.9M
2016
Grant
$600K
2020
Debt
$350K
Epivax Tech Stack
A closer look at the technologies used by Epivax
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Sales, Compliance, Logistics / Supply Chain, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Manufacturing Operations, Operations
Funding
Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Epivax News & Media
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
PROVIDENCE, R.I., Dec. 21, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed EpiVax's ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai's robust biologics pipeline. The ISPRI toolkit is a secure web-based platform that allows researchers to rapidly assess the immunogenic risk of biologic candidates. The fully integrated computational immunology toolkit cEpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
PROVIDENCE, R.I., Dec. 20, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed EpiVax's ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai's robust...Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach
PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M contract spanning two years...Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach
PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M contract spanning two years...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Epivax
Sign Up For FreeTo access detailed company insights
EpiVax is an American biotechnology firm headquartered in Providence, Rhode Island that specialises in immunoinformatics and immunogenicity risk assessment to support vaccine and biologic drug development. The company uses advanced computational and laboratory methods to help partners optimise therapeutic safety and efficacy and mitigate immune res... Read More
